GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

This was the stock's second consecutive day of gains.

There was a mix-up regarding my appointment for blood testing this morning. I arrived on time for my appointment but the kiosk indicated no appointment scheduled. It was 10 minutes to 12 (office ...